Skip to Main Content

Skip Nav Destination

.Getting the Most from Minimal Residual Disease| November 5, 2020

Bioengineering Strategies to Phenotypically Define Minimal Residual Disease

Scott R. Manalis, PhD

Scott R. Manalis, PhD

1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA

Search for other works by this author on:

PubMed

Google Scholar

Blood (2020) 136 (Supplement 1): SCI2.

https://doi.org/10.1182/blood-2020-133039

Sign in via your Institution

Supplemental data